Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2023 | Interim analysis of a study evaluating pivekimab sunirine in patients with BPDCN

Naveen Pemmaraju • 3 Jun 2023
EHA 2023
Blastic Plasmacytoid Dendritic Cell Neoplasm Rare Diseases Antibodies Pivekimab sunirine Tagraxofusp

Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results from an interim analysis of a study evaluating the CD123-targeting antibody-drug conjugate (ADC) pivekimab sunirine in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Naveen Pemmaraju

1:40
TAG-AZA-VEN in the treatment of patients with newly diagnosed CD123+ AML
Naveen Pemmaraju • 11 Dec 2023
1:29
Exciting developments in the field of BPDCN
Naveen Pemmaraju • 11 Dec 2023
1:58
TRANSFORM-1: navitoclax + ruxolitinib vs placebo + ruxolitinib in patients with untreated MF
Naveen Pemmaraju • 11 Dec 2023
1:15
Exploring the evolving treatment landscape of myelofibrosis
Naveen Pemmaraju • 3 Jun 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals